These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
336 related articles for article (PubMed ID: 24484609)
1. The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluation. Loveman E; Jones J; Clegg AJ; Picot J; Colquitt JL; Mendes D; Breen DJ; Moore E; George S; Poston G; Cunningham D; Ruers T; Primrose J Health Technol Assess; 2014 Jan; 18(7):vii-viii, 1-283. PubMed ID: 24484609 [TBL] [Abstract][Full Text] [Related]
2. Ablative and non-surgical therapies for early and very early hepatocellular carcinoma: a systematic review and network meta-analysis. Wade R; South E; Anwer S; Sharif-Hurst S; Harden M; Fulbright H; Hodgson R; Dias S; Simmonds M; Rowe I; Thornton P; Eastwood A Health Technol Assess; 2023 Dec; 27(29):1-172. PubMed ID: 38149643 [TBL] [Abstract][Full Text] [Related]
3. Ablative therapy for people with localised prostate cancer: a systematic review and economic evaluation. Ramsay CR; Adewuyi TE; Gray J; Hislop J; Shirley MD; Jayakody S; MacLennan G; Fraser C; MacLennan S; Brazzelli M; N'Dow J; Pickard R; Robertson C; Rothnie K; Rushton SP; Vale L; Lam TB Health Technol Assess; 2015 Jul; 19(49):1-490. PubMed ID: 26140518 [TBL] [Abstract][Full Text] [Related]
4. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation. Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208 [TBL] [Abstract][Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation. Huxley N; Crathorne L; Varley-Campbell J; Tikhonova I; Snowsill T; Briscoe S; Peters J; Bond M; Napier M; Hoyle M Health Technol Assess; 2017 Jun; 21(38):1-294. PubMed ID: 28682222 [TBL] [Abstract][Full Text] [Related]
6. Liver resection surgery compared with thermal ablation in high surgical risk patients with colorectal liver metastases: the LAVA international RCT. Davidson B; Gurusamy K; Corrigan N; Croft J; Ruddock S; Pullan A; Brown J; Twiddy M; Birtwistle J; Morris S; Woodward N; Bandula S; Hochhauser D; Prasad R; Olde Damink S; Coolson M; Laarhoven KV; de Wilt JH Health Technol Assess; 2020 Apr; 24(21):1-38. PubMed ID: 32370822 [TBL] [Abstract][Full Text] [Related]
8. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920 [TBL] [Abstract][Full Text] [Related]
9. A systematic review of the clinical effectiveness and cost-effectiveness of Pharmalgen® for the treatment of bee and wasp venom allergy. Hockenhull J; Elremeli M; Cherry MG; Mahon J; Lai M; Darroch J; Oyee J; Boland A; Dickson R; Dundar Y; Boyle R Health Technol Assess; 2012; 16(12):III-IV, 1-110. PubMed ID: 22409877 [TBL] [Abstract][Full Text] [Related]
10. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cirocchi R; Trastulli S; Boselli C; Montedori A; Cavaliere D; Parisi A; Noya G; Abraha I Cochrane Database Syst Rev; 2012 Jun; (6):CD006317. PubMed ID: 22696357 [TBL] [Abstract][Full Text] [Related]
11. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model. Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747 [TBL] [Abstract][Full Text] [Related]
12. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection. Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408 [TBL] [Abstract][Full Text] [Related]
13. Transarterial (chemo)embolisation versus no intervention or placebo for liver metastases. Swierz MJ; Storman D; Riemsma RP; Wolff R; Mitus JW; Pedziwiatr M; Kleijnen J; Bala MM Cochrane Database Syst Rev; 2020 Mar; 3(3):CD009498. PubMed ID: 32163181 [TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840 [TBL] [Abstract][Full Text] [Related]
15. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation. Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018 [TBL] [Abstract][Full Text] [Related]
16. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574 [TBL] [Abstract][Full Text] [Related]
17. The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation. Takeda AL; Jones J; Loveman E; Tan SC; Clegg AJ Health Technol Assess; 2007 May; 11(19):iii, ix-xi, 1-62. PubMed ID: 17462169 [TBL] [Abstract][Full Text] [Related]
18. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Edwards SJ; Barton S; Thurgar E; Trevor N Health Technol Assess; 2015 Jan; 19(7):1-480. PubMed ID: 25626481 [TBL] [Abstract][Full Text] [Related]
19. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model. Tappenden P; Carroll C; Hamilton J; Kaltenthaler E; Wong R; Wadsley J; Moss L; Balasubramanian S Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231 [TBL] [Abstract][Full Text] [Related]